Fig. 2 | British Journal of Cancer

Fig. 2

From: A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

Fig. 2

Overall survival and progression-free survival of all patients from cycle 1, day 1 (C1D1) of study treatment. E/N, Number of patients with the event (death for OS and disease progression for PFS) / Total number of evaluable patients. Among the 35 patients, 19 (54.2%) died. The median OS time was 2.63 years (95% CI: 1.36-NA), and the median follow-up time was 2.53 years (95% CI: 1.77, 4.30)

Back to article page